Combination comprising a signal transduction inhibitor and an epothilone derivative

US7723339B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Ralf Brandt · Salisbury, AU
• Elisabeth Buchdunger · Neuenbürg, DE
• Carl-Henrik Heldin · Uppsala, SE
• Arne Ostman · Uppsala, SE
• Kristian Pietras · Stockholm, SE
• Terence O'Reilly · Basel, CH
• John David Rothermel · Sunset Beach, US
• Peter Traxler · Allschwil, CH
• Markus Wartmann · Riehen, CH

Key dates

• Filing date: Feb 26, 2002
• Grant date: May 25, 2010
• Expiry date: Oct 27, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.